Modern pharmacotherapy A.D. 2023 – why, when and for whom to use clonidine? Case study Case report

Article Sidebar

Requires Subscription PDF (Język Polski)
Purchase article

Published: Nov 30, 2023
DOI: https://doi.org/10.24292/01.MF.0323.19
Keywords:
clonidine, arterial hypertension, urgent conditions, resistant hypertension

Main Article Content

Marcin Barylski
1. Klinika Chorób Wewnętrznych i Rehabilitacji Kardiologicznej, Uniwersytet Medyczny w Łodzi. 2. Uniwersytecki Szpital Kliniczny im. Wojskowej Akademii Medycznej – Centralny Szpital Weteranów

Abstract

Clonidine is a hypotensive drug that inhibits the activity of the sympathetic nervous system by affecting the α2-adrenergic receptors and, to a lesser extent, the imidazole receptors located in the central nervous system. The haemodynamic effect of the drug consists in reducing peripheral resistance, cardiac output and heart rate. It is characterized by good absorption from the gastrointestinal tract, rapid onset of hypotensive effect and no effect on renal blood flow, therefore it can be used in patients with arterial hypertension coexisting with chronic kidney disease. According to the current guidelines of the Polish Society of Hypertension from 2019, the use of clonidine is recommended both temporarily in urgent conditions and chronically – as part of polytherapy for resistant hypertension. It should be emphasized that clonidine is a drug that can also be used in women of childbearing age, when necessary.

Article Details

How to Cite
Barylski , M. (2023). Modern pharmacotherapy A.D. 2023 – why, when and for whom to use clonidine? Case study. Medycyna Faktow (J EBM), 16(3(60), 384-389. https://doi.org/10.24292/01.MF.0323.19
Issue
Vol 16 No 3(60) (2023)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Mancia G, Kreutz R, Brunström M et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023 (w druku).
2. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-84.
3. Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007; 9(5): 399-405.
4. Januszewicz A, Dobrowolski P, Prejbisz A. Klonidyna – nowe miejsce w terapii nadciśnienia tętniczego. Terapia. 2022; 7: 84-91.
5. Charakterystyka produktu leczniczego Iporel, 75 μg, tabletki; 07.2020.
6. Hanna J, Ghazi L, Yamamoto Y et al. Excessive Blood Pressure Response to Clonidine in Hospitalized Patients With Asymptomatic Severe Hypertension. Am J Hypertens. 2022; 35(5): 433-40.
7. Warchoł-Celińska E, Prejbisz A, Dobrowolski P et al. Klonidyna w terapii nadciśnienia tętniczego – od stanów pilnych po terapię trudnego w kontroli nadciśnienia tętniczego. Terapia. 2019; 10(381): 20-5.
8. Williams B, MacDonald TM, Morant S et al.; British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015; 386(10008): 2059-68.
9. Krieger EM, Drager LF, Giorgi DMA et al.; ReHOT Investigators. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension. 2018; 71(4): 681-90.